1S1.F VIRIDIAN THERAPEUTICS

Healthcare Biotechnology Frankfurt Exchange
27.60 EUR
Close of Nov 11, 2026
11.20 28.58
Market cap
EUR 3.13B
P/E
-
P/B
7.02x
ROE
-76.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1S1.F undervalued?

Graham number

The Graham number of VIRIDIAN THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VIRIDIAN THERAPEUTICS fundamental analysis

No fundamental analysis for VIRIDIAN THERAPEUTICS yet.

VIRIDIAN THERAPEUTICS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VIRIDIAN THERAPEUTICS

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatme…

Full company profile